# SYMPATICO (NCT03112174)

> Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03112174
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Pharmacyclics LLC.
- Conditions: Mantle-Cell Lymphoma
- Interventions: Ibrutinib; Venetoclax; Placebo Oral tablet to match Venetoclax
- Enrollment: 366
- Primary outcome: Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in)
- Primary outcome: Number of Participants With Dose Limiting Toxicities (DLT) (Safety Run-in)
- Primary outcome: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (Safety Run-in)
- Primary outcome: Progression-free Survival (PFS) (Randomization Phase)
- Primary outcome: Complete Response (CR) Rate (Treatment-Naive Arm)

## Commentary we found

- YouTube: 38
- Podcasts: 25
- X threads: 25

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sympatico-nct03112174

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03112174", "email": "<work email>"}; the inbox owner confirms by the emailed link.